Novo Nordisk Operating Margin 1988-2025 | NVO

Current and historical operating margin for Novo Nordisk (NVO) over the last 10 years. The current operating profit margin for Novo Nordisk as of June 30, 2025 is 32.53%.
Novo Nordisk Operating Margin Historical Data
Date TTM Revenue TTM Operating Income Operating Margin
2025-06-30 $45.48B $20.79B 45.71%
2025-03-31 $43.61B $19.45B 44.59%
2024-12-31 $42.11B $18.61B 44.19%
2024-09-30 $39.37B $17.24B 43.77%
2024-06-30 $37.44B $16.18B 43.22%
2024-03-31 $35.55B $15.93B 44.80%
2023-12-31 $33.72B $14.89B 44.16%
2023-09-30 $30.85B $13.37B 43.33%
2023-06-30 $28.44B $12.17B 42.79%
2023-03-31 $26.41B $11.31B 42.83%
2022-12-31 $25.06B $10.59B 42.28%
2022-09-30 $24.32B $10.34B 42.50%
2022-06-30 $23.81B $10.02B 42.10%
2022-03-31 $23.26B $9.79B 42.09%
2021-12-31 $22.40B $9.33B 41.65%
2021-09-30 $21.64B $9.07B 41.92%
2021-06-30 $20.85B $8.67B 41.57%
2021-03-31 $19.93B $8.31B 41.73%
2020-12-31 $19.45B $8.29B 42.64%
2020-09-30 $19.09B $8.21B 43.02%
2020-06-30 $18.74B $8.13B 43.35%
2020-03-31 $18.84B $8.11B 43.05%
2019-12-31 $18.29B $7.87B 43.01%
2019-09-30 $17.43B $7.49B 42.98%
2019-06-30 $17.25B $7.41B 42.95%
2019-03-31 $17.11B $7.34B 42.87%
2018-12-31 $17.10B $7.22B 42.25%
2018-09-30 $17.61B $7.47B 42.43%
2018-06-30 $17.49B $7.53B 43.08%
2018-03-31 $17.33B $7.56B 43.61%
2017-12-31 $16.97B $7.44B 43.84%
2017-09-30 $16.81B $7.43B 44.22%
2017-06-30 $16.73B $7.39B 44.18%
2017-03-31 $16.67B $7.31B 43.86%
2016-12-31 $16.61B $7.20B 43.33%
2016-09-30 $16.56B $7.20B 43.49%
2016-06-30 $16.43B $7.13B 43.38%
2016-03-31 $16.26B $7.08B 43.51%
2015-12-31 $16.06B $7.36B 45.81%
2015-09-30 $15.99B $7.28B 45.55%
2015-06-30 $15.95B $7.02B 44.01%
2015-03-31 $15.92B $6.78B 42.57%
2014-12-31 $15.83B $6.15B 38.84%
2014-09-30 $15.63B $5.95B 38.08%
2014-06-30 $15.31B $5.85B 38.18%
2014-03-31 $15.08B $5.75B 38.09%
2013-12-31 $14.89B $5.61B 37.68%
2013-09-30 $14.58B $5.59B 38.30%
2013-06-30 $14.27B $5.49B 38.45%
2013-03-31 $13.89B $5.31B 38.19%
2012-12-31 $13.48B $5.09B 37.77%
2012-09-30 $13.04B $4.83B 37.06%
2012-06-30 $12.80B $4.51B 35.23%
2012-03-31 $12.52B $4.18B 33.41%
2011-12-31 $12.27B $4.05B 33.02%
2011-09-30 $12.04B $3.90B 32.36%
2011-06-30 $11.85B $3.97B 33.54%
2011-03-31 $11.48B $3.90B 33.97%
2010-12-31 $11.06B $3.59B 32.46%
2010-09-30 $10.66B $3.21B 30.14%
2010-06-30 $10.24B $2.94B 28.74%
2010-03-31 $9.90B $2.77B 27.96%
2009-12-31 $9.67B $2.77B 28.68%
2009-09-30 $9.31B $2.76B 29.68%
2009-06-30 $9.10B $2.62B 28.78%
2009-03-31 $8.21B $1.61B 19.58%
2008-12-31 $8.12B $1.47B 18.13%
2008-09-30 $8.02B $1.17B 14.63%
2008-06-30 $7.69B $1.00B 13.03%
2008-03-31 $8.11B $1.76B 21.71%
2007-12-31 $7.71B $1.59B 20.69%
2007-09-30 $7.59B $1.92B 25.37%
2007-06-30 $7.24B $1.81B 25.02%
2007-03-31 $6.44B $1.23B 19.06%
2006-12-31 $6.16B $1.14B 18.45%
2006-09-30 $5.81B $0.96B 16.51%
2006-06-30 $5.73B $1.03B 17.90%
2006-03-31 $6.02B $1.53B 25.39%
2005-12-31 $5.86B $1.51B 25.68%
2005-09-30 $5.61B $0.70B 12.52%
2005-06-30 $5.36B $0.57B 10.55%
2005-03-31 $5.13B $0.46B 8.96%
2004-12-31 $4.96B $1.18B 23.76%
2004-09-30 $4.70B $1.98B 42.15%
2004-06-30 $4.46B $1.89B 42.37%
2004-03-31 $4.27B $1.79B 41.95%
2003-12-31 $4.06B $0.98B 24.24%
2003-09-30 $4.13B $0.83B 20.12%
2003-06-30 $3.97B $0.82B 20.56%
2003-03-31 $3.78B $0.78B 20.64%
2002-12-31 $3.54B $0.70B 19.77%
2002-09-30 $3.06B $-0.96B -31.34%
2002-06-30 $2.91B $-0.48B -16.41%
2002-03-31 $2.80B $0.03B 1.07%
2001-12-31 $2.82B $0.56B 19.77%
2001-09-30 $2.49B $0.33B 13.40%
2001-06-30 $2.43B $0.30B 12.16%
2001-03-31 $2.53B $0.42B 16.44%
2000-12-31 $2.59B $0.51B 19.85%
2000-09-30 $2.95B $2.95B 100.00%
2000-06-30 $3.09B $3.09B 100.00%
2000-03-31 $3.02B $3.02B 100.00%
1999-12-31 $2.96B $2.96B 100.00%
1999-09-30 $2.94B $2.94B 100.00%
1999-06-30 $2.82B $2.82B 100.00%
1999-03-31 $2.75B $2.75B 100.00%
1998-12-31 $2.68B $2.68B 100.00%
1998-09-30 $2.60B $2.60B 100.00%
1998-06-30 $2.65B $2.65B 100.00%
1998-03-31 $2.61B $2.61B 100.00%
1997-12-31 $2.58B $2.58B 100.00%
1997-09-30 $2.60B $2.60B 100.00%
1997-06-30 $2.53B $2.53B 100.00%
1997-03-31 $2.52B $2.52B 100.00%
1996-12-31 $2.56B $2.56B 100.00%
1996-09-30 $2.48B $2.48B 100.00%
1996-06-30 $2.45B $2.45B 100.00%
1996-03-31 $2.48B $2.48B 100.00%
1995-12-31 $2.46B $2.46B 100.00%
1995-09-30 $2.43B $2.43B 100.00%
1995-06-30 $2.36B $2.36B 100.00%
1995-03-31 $2.25B $2.25B 100.00%
1994-12-31 $2.14B $2.14B 100.00%
1994-09-30 $2.04B $2.04B 100.00%
1994-06-30 $1.96B $1.96B 100.00%
1994-03-31 $1.87B $1.87B 100.00%
1993-12-31 $1.84B $1.84B 100.00%
1993-06-30 $1.30B $1.30B 100.00%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $424.453B $25.059B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $495.141B 66.87
Johnson & Johnson (JNJ) United States $450.090B 16.68
Merck (MRK) United States $270.018B 37.87
AbbVie (ABBV) United States $264.086B 11.85
AstraZeneca (AZN) United Kingdom $218.471B 19.74
Novartis AG (NVS) Switzerland $218.425B 15.54
Pfizer (PFE) United States $201.199B 7.39
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12